# TLRY earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TLRY) · [Earnings tab](https://www.lopjlb.com/stock/TLRY?tab=earnings) Updated: 2026-10-08T05:52:16 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarters, Tilray's narrative evolved from beverage integration execution and Canadian cannabis share recovery toward a diversified, international medical cannabis and beverage platform with a net cash balance sheet. Early calls (2025 Q1–Q2) centered on ABI brand integration risk, Project 420 cost savings, and regaining Canadian leadership in flower and THC beverages. By 2025 Q3–Q4, emphasis shifted to profitability, debt reduction, and international medical ## Latest CallCard · Q4 Tilray reports record $915M revenue, $61M adjusted EBITDA and positive cash flow, highlighting diversification across cannabis, beverage, hospitality and wellness while noting European permit delays and price compression. **Guidance:** maintained — No explicit change to guidance was provided. **Tone:** mgmt 0.7 · Q&A pressure 0.5 · divergence 0.3 Prepared remarks emphasized record results, diversified growth and disciplined capital allocation, portraying an upbeat outlook. ### Demand visibility Improved demand visibility via integrated medical platform Life acquisition connects cultivation, manufacturing, clinical care, dispensing and pharmacy services, giving direct patient access and stronger demand visibility across the patient journey. ### Margins / costs Cost control and margin protection through supply expansion and cost reductions Reduced cost per unit >30% since FY2025; working to protect margins as Portugal facility ramps to full capacity and addressing European price compression. ### Capital allocation Disciplined capital allocation to high‑return assets Invested ~$50M working capital into BrewDog, allocated capital to supply expansion, permit acceleration and Life acquisition, and reduced debt by $60M. ### Milestones - **BrewDog acquisition** [delivered]: Acquired for $54M, integrated and $50M working capital invested, stabilizing operations. - **Portugal cultivation facility** [at_risk]: Reached ~80% utilization, path to full capacity pending permits. - **Germany Aphria RX facility** [delivered]: Fully utilized and ARX brand launched with strong early patient response. - **Life acquisition integration** [on_track]: Provides end‑to‑end medical cannabis services, enhancing demand visibility. - **Carlsberg partnership** [new]: Beer production for Carlsberg to start Jan 1. - **US craft beer expansion via BrewDog** [on_track]: Launched 23 American craft beers. ### Fears / risks - **Regulatory risk**: Permit delays in Europe and uncertain US cannabis rescheduling. - **Price compression**: European market experienced $21M price compression impacting margins. - **Market competition**: Highly competitive Canadian cannabis market despite leading share. - **Supply chain**: Need to secure supply to meet growing demand, especially in Portugal. - **Margin pressure**: Protecting margins as Portugal facility ramps to full capacity. - **Hemp product restrictions**: Delta‑9 hemp products face potential regulatory blockage. - **Debt/financial risk**: Although debt reduced, maintaining cash balance is critical. - **Consumer demand volatility**: Beer market softness and changing consumer preferences. ### Key quotes > “We delivered record revenue of over $915 million on an annualized pro forma basis.” > “Positive cash flow from operations, excluding working capital, improved to approximately $18 million, an increase of over $50 million year-over-year.” > “A big part of the growth is having supply where we did not have supply throughout last year.” — Irwin Simon ## Quarter one-liners - **2026 Q4:** Tilray reports record $915M revenue, $61M adjusted EBITDA and positive cash flow, highlighting diversification across cannabis, beverage, hospitality and wellness while noting European permit delays and price compression. - **2026 Q3:** Tilray posted a record Q3 with 11% revenue growth, expanded internationally, launched BrewDog acquisition and Carlsberg partnership, but flagged integration and regulatory challenges. - **2026 Q2:** Tilray reports record Q2 revenue of $218M, adjusted EBITDA $8.4M, strong balance sheet with $292M cash, net cash position; international cannabis revenue up 51% sequentially; US rescheduling catalyst; beverage integration on track for $33M cost savings. - **2026 Q1:** Tilray Q1 FY26: revenue +5% YoY to $210M record, net income $1.5M, debt reduced, Project 420 on track ($25M/$33M savings), Canadian cannabis share gains, international expansion advancing, US rescheduling optimism, but beverage flat and spirits tough. - **2025 Q4:** — - **2025 Q3:** Tilray reports Q3 net revenue $186M ($193M constant currency), adjusted up 10% to $206M excluding strategic decisions; gross margin expands 200bps to 28%, cannabis margin up 800bps to 41%; focuses on profitability, debt reduction, and international medical cannabis growth. - **2025 Q2:** Tilray Q2 FY25: revenue +9% YoY to $211M, gross margin +500bps QoQ; beverage +36% YoY, cannabis Canada #1, international +25%; Project 420 $17M/$25M savings achieved; maintaining $1B revenue guidance. - **2025 Q1:** Tilray posted record Q1 revenue, boosted margins and beverage growth, but flagged timing and integration issues in its beverage segment, while maintaining $950-$1B annual guidance. ## Guidance path 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague → 2026 Q3:vague → 2026 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/TLRY`